Comparative Pharmacology
Head-to-head clinical analysis: CALDOLOR versus XIBROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALDOLOR versus XIBROM.
CALDOLOR vs XIBROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing synthesis of prostaglandins involved in inflammation, pain, and fever.
XIBROM (bromfenac) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing intraocular inflammation.
800 mg IV every 8 hours as a 30-minute infusion; alternatively, 400 mg IV every 6 hours. Maximum daily dose: 2400 mg.
Instill 1 drop into the affected eye(s) 4 times daily starting 24 hours before surgery and continuing for 2 weeks postoperatively.
None Documented
None Documented
2-4 hours (terminal half-life). Clinical context: Requires dosing every 6-8 hours for sustained effect; no accumulation with normal hepatic function.
Terminal elimination half-life is approximately 42 hours. Clinical context: Due to its long half-life, steady-state is achieved after about 8 days of daily dosing, which contributes to sustained anti-inflammatory effect.
Renal (primarily as glucuronide conjugates and inactive metabolites; <10% unchanged). Biliary/fecal elimination is negligible.
Renal: ~70% (primarily as unchanged drug); Biliary/Fecal: ~15% (as metabolites); the remainder is eliminated via other minor pathways.
Category C
Category C
NSAID
NSAID